NBTX — Nanobiotix SA Share Price
Last trade - 00:00- $196.46m
- $228.19m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.12 | 0.07 | 0.05 | 0.01 | n/a | 13.68 | 38.25 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Directors
- Gary Phillips CSU (55)
- Laurent Levy CMG (49)
- Anne-Marie Graffin VSU (60)
- Bart Van Rhijn CFO
- Alain Dostie COO
- Anne-Juliette Hermant CHO (47)
- Alain Herrera IND (69)
- Enno Spillner IND (51)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- March 1st, 2003
- Public Since
- October 29th, 2012
- No. of Employees
- 101
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 35,230,382
- Address
- 60 rue de Wattignies, PARIS, 75012
- Web
- https://www.nanobiotix.com
- Phone
- +33 140260470
- Contact
- Craig West
- Auditors
- Ernst & Young et Autres
Similar to NBTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:14 UTC, shares in Nanobiotix SA are trading at $6.09. This share price information is delayed by 15 minutes.
Shares in Nanobiotix SA last closed at $6.09 and the price had moved by +54.18% over the past 365 days. In terms of relative price strength the Nanobiotix SA share price has outperformed the S&P500 Index by +24.51% over the past year.
The overall consensus recommendation for Nanobiotix SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Nanobiotix SA does not currently pay a dividend.
Nanobiotix SA does not currently pay a dividend.
Nanobiotix SA does not currently pay a dividend.
To buy shares in Nanobiotix SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.09, shares in Nanobiotix SA had a market capitalisation of $196.46m.
Here are the trading details for Nanobiotix SA:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NBTX
Based on an overall assessment of its quality, value and momentum Nanobiotix SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nanobiotix SA is $11.91. That is 95.54% above the last closing price of $6.09.
Analysts covering Nanobiotix SA currently have a consensus Earnings Per Share (EPS) forecast of -€1.41 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nanobiotix SA. Over the past six months, its share price has underperformed the S&P500 Index by -22.41%.
As of the last closing price of $6.09, shares in Nanobiotix SA were trading -14.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nanobiotix SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nanobiotix SA's management team is headed by:
- Gary Phillips - CSU
- Laurent Levy - CMG
- Anne-Marie Graffin - VSU
- Bart Van Rhijn - CFO
- Alain Dostie - COO
- Anne-Juliette Hermant - CHO
- Alain Herrera - IND
- Enno Spillner - IND